[1] 李阳, 肖丽, 叶茂聪, 等. 低病毒载量HBeAg阴性慢性HBV感染者肝组织学特点及不同诊断指标对非活动携带的诊断价值. 肝脏, 2017, 22:789-793.
[2] 盛秋菊, 丁洋, 李佰君,等. HBV感染免疫耐受期孕妇应用替比夫定阻断母婴传播有效性及停药安全性的研究. 中华肝脏病杂志, 2016, 24:258-264.
[3] 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2010年版). 肝脏, 2011, 3:66-82.
[4] 庄辉. 预防乙型肝炎病毒母婴传播中值得注意的几个问题. 中华肝脏病杂志, 2016, 24:881-884.
[5] Wen WH, Lai MW, Chang MH. A review of strategies to prevent mother-to-infant transmission of hepatitis b virus infection. Expert Rev Gastroent, 2016, 10:317-330.
[6] Ding Y. Efficacy and safety of nucleos(t)ide analogues to prevent hepatitis B virus mother-to-child transmission in pregnant women with high viremia: real life practice from China:. Int J Med Sci, 2018, 15:796-801.
[7] Zeng H, Cai H, Wang Y, et al. Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers. Int J Infect Dis, 2015, 33:97-103.
[8] Liu Y, Wang M, Yao S, et al. Efficacy and safety of telbivudine in different trimesters of pregnancy with high viremia for interrupting perinatal transmission of HBV. Hepatol Res, 2015, 46:135-145. |
